For example, Pollyea et al. [40] demonstrated that the combination of venetoclax, a BCL-2 inhibitor, and azacitidine disrupted mitochondrial metabolism and effectively targeted leukemia stem cells, leading to better clinical outcomes in patients with AML. This evidence concerns the gene BCL2 and acute myeloid leukemia.